Yoichiro Takami
Overview
Explore the profile of Yoichiro Takami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Izushi Y, Takami Y, Ushio S, Tetsunaga T, Shiota N, Yamamoto H, et al.
Medicine (Baltimore)
. 2022 Dec;
101(47):e31298.
PMID: 36451476
Edoxaban (Edx) has been approved to prevent venous thromboembolism after total knee and/or hip arthroplasty in Japan. However, the risk of anemia with Edx treatment remains elusive. No risk factors...
2.
Moriyama K, Yakushige A, Yamamoto M, Ogura Y, Fukushima S, Kamei T, et al.
Yakugaku Zasshi
. 2018 Sep;
138(12):1561-1568.
PMID: 30210065
Hospital formulation has several advantages, including the flexibility of customization as per the disease state or the patients' precise requirements. However, compared with commercial formulations, hospital formulations are usually not...
3.
Izushi Y, Shiota N, Tetsunaga T, Shimada K, Egawa T, Kiuchi T, et al.
Eur J Orthop Surg Traumatol
. 2018 May;
28(7):1349-1358.
PMID: 29730743
Background: Postoperative anemia is a common complication after total hip arthroplasty (THA). However, the effect of edoxaban on postoperative anemia after THA remains unclear. Here, we retrospectively evaluated the clinical...
4.
Kudo K, Ohashi K, Makimoto G, Higo H, Kato Y, Kayatani H, et al.
Mol Oncol
. 2017 Apr;
11(6):670-681.
PMID: 28388009
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment strategy for EGFR-mutant lung cancers; however, resistance usually occurs due to a secondary mutation, T790M, in EGFR....
5.
Izushi Y, Takami Y, Shiota N, Tetsunaga T, Ookura Y, Shimada K, et al.
Biol Pharm Bull
. 2016 Apr;
39(4):516-23.
PMID: 27040624
Edoxaban, an oral direct factor Xa inhibitor, was developed and approved for anticoagulant thromboprophylaxis after total knee arthroplasty (TKA). We retrospectively investigated the postoperative anemia by oral administration of edoxaban...
6.
Moriyama K, Takami Y, Uozumi N, Okuda A, Yamashita M, Yokomizo R, et al.
J Pharm Health Care Sci
. 2016 Feb;
2:4.
PMID: 26865984
Background: Atropine sulfate is an anticholinergic agent for treatment of hypertrophic pyloric stenosis and is orally administrated as a triturate with lactose hydrate. Because of the low safety margin of...
7.
Hanada T, Takami Y, Moriyama K, Oro M, Ogawa T, Moriyasu H, et al.
J Pharm Health Care Sci
. 2016 Jan;
1:20.
PMID: 26819731
Background: Unintended exposure to antitumor agents from an oral medicine may place healthcare workers and patients taking medicine at risk. In this study, the exposure to blister pack by CP...
8.
Kumagai K, Tabu K, Sasaki F, Takami Y, Morinaga Y, Mawatari S, et al.
PLoS One
. 2015 Nov;
10(11):e0143413.
PMID: 26599547
Background And Aims: Glycoprotein nonmetastatic melanoma B (Gpnmb), a transmembrane glycoprotein that is expressed in macrophages, negatively regulates inflammation. We have reported that Gpnmb is strongly expressed in the livers...
9.
Sasaki F, Kumagai K, Uto H, Takami Y, Kure T, Tabu K, et al.
Mol Med Rep
. 2015 Oct;
12(5):7503-11.
PMID: 26458492
Glycoprotein nonmetastatic melanoma protein B (Gpnmb) is a transmembrane glycoprotein, which negatively regulates the inflammatory responses of macrophages. However, the role of Gpnmb in intestinal macrophages remains to be fully...
10.
Hamasaki M, Hashizume Y, Yamada Y, Katayama T, Hohjoh H, Fusaki N, et al.
Stem Cells
. 2012 Sep;
30(11):2437-49.
PMID: 22949078
Fibrodysplasia ossificans progressiva (FOP) is a rare congenital disorder characterized by progressive ossification of soft tissues. FOP is caused by mutations in activin receptor-like kinase 2 (ALK2) that cause its...